Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · HARVARD BIOSCIENCE INC (HBIO)

Harvard Bioscience Q2 revenue rises 11% to $22.7 million; raises 2026 revenue outlook

Mixed Impact 4 of 5 earnings Written later

Harvard Bioscience reported second quarter 2026 revenue of $22.7 million, up 11% from $20.5 million a year earlier, and raised its full-year 2026 revenue growth guidance to 3% to 5%. The company's GAAP net loss widened to $2.9 million from $2.3 million, so the sales gain came with a larger loss for shareholders.

Key points

  • Q2 2026 revenue of $22.7 million vs. $20.5 million in Q2 2025; foreign currency added about 1%
  • Q2 2026 net loss of $2.9 million vs. $2.3 million in Q2 2025; adjusted EBITDA rose to $1.7 million from $1.5 million
  • Full-year 2026 revenue growth guidance raised to 3% to 5%; adjusted gross margin target lowered to 57% to 59%
  • Third quarter 2026 revenue guidance of $21.0 million to $22.6 million

The filing

CompanyHARVARD BIOSCIENCE INC (HBIO)
Form8-K, current report
Filed with the SECAug 11, 2026, 7:00 AM ET
Accession number0001171843-26-005405

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.